Drug Type Antibody drug conjugate (ADC) |
Synonyms CD99/Irinotecan nanoparticles, antiCD99 TNS (CD99TNS/Ir) |
Target |
Mechanism CD99 inhibitors(CD99 molecule (Xg blood group) inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma Multiforme | Preclinical | US | 30 Jan 2022 | |
Ewing Sarcoma | Preclinical | US | - |